192 related articles for article (PubMed ID: 31128215)
1. The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Li Y; Acharya G; Elahy M; Xin H; Khachigian LM
Cancer Lett; 2019 Sep; 459():268-276. PubMed ID: 31128215
[TBL] [Abstract][Full Text] [Related]
2. Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.
Li Y; Wu B; Hossain MJ; Quagliata L; O'Meara C; Wilkins MR; Corley S; Khachigian LM
J Transl Med; 2023 Jul; 21(1):467. PubMed ID: 37452307
[TBL] [Abstract][Full Text] [Related]
3. Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent.
Khachigian LM
Cancer Lett; 2021 Dec; 522():57-62. PubMed ID: 34520820
[TBL] [Abstract][Full Text] [Related]
4. Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma.
Kim SH; Li M; Trousil S; Zhang Y; Pasca di Magliano M; Swanson KD; Zheng B
J Invest Dermatol; 2017 Aug; 137(8):1740-1748. PubMed ID: 28433543
[TBL] [Abstract][Full Text] [Related]
5. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.
Hou ZJ; Luo X; Zhang W; Peng F; Cui B; Wu SJ; Zheng FM; Xu J; Xu LZ; Long ZJ; Wang XT; Li GH; Wan XY; Yang YL; Liu Q
Oncotarget; 2015 Mar; 6(8):6326-40. PubMed ID: 25811972
[TBL] [Abstract][Full Text] [Related]
6. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy.
Lin S; Yang L; Yao Y; Xu L; Xiang Y; Zhao H; Wang L; Zuo Z; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jul; 38(1):293. PubMed ID: 31287013
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
Lin H; Wu Y; Chen J; Huang S; Wang Y
Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
[TBL] [Abstract][Full Text] [Related]
9. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
10. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
12. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.
Ajona D; Ortiz-Espinosa S; Moreno H; Lozano T; Pajares MJ; Agorreta J; Bértolo C; Lasarte JJ; Vicent S; Hoehlig K; Vater A; Lecanda F; Montuenga LM; Pio R
Cancer Discov; 2017 Jul; 7(7):694-703. PubMed ID: 28288993
[TBL] [Abstract][Full Text] [Related]
13. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy.
Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980
[TBL] [Abstract][Full Text] [Related]
14. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
[TBL] [Abstract][Full Text] [Related]
15. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
[TBL] [Abstract][Full Text] [Related]
16. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
17. Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers.
Chen C; Ding Y; Liu H; Sun M; Wang H; Wu D
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008943
[TBL] [Abstract][Full Text] [Related]
18. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
[TBL] [Abstract][Full Text] [Related]
19. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
